Syndrome main-pied

  • aflibercept (Zaltrap®)
  • axitinib (Inlyta®)
  • bevacizumab (Avastin®)
  • cabozantinib (Cabometyx®)
  • lenvatinib (Lenvima®)
  • pazopanib (Votrient®)
  • regorafenib (Stivarga®)
  • sorafenib (Nexavar®)
  • sunitinib (Sutent®)
  • vandetanib (Caprelsa®)
  • afatinib (Giotrif®)
  • cetuximab (Erbitux®)
  • erlotinib (Tarceva®)
  • panitumumab (Vectibix®)
  • lapatinib (Tyverb®)
  • T-DM1/ trastuzumab emtansine (Kadcyla®)
  • trastuzumab (Herceptin®)
  • dabrafenib (Tafinlar®)
  • rucaparib (Rubraca®)
  • encorafenib (Braftovi®)
  • vemurafenib (Zelboraf®)
  • binimetinib (Mektovi®)
  • trametinib (Mekinist®)
  • evérolimus (Afinitor®)
  • vismodegib (Erivedge®)
  • imatinib (Glivec®)